In patients who received the vaccination, progression-free survival (PFS) at 6 months was 33.3%, and the median overall survival (OS) was 36.7 weeks, suggesting the therapeutic potential of WT1 peptide vaccine for GBM patients [10]. This evidence concerns the gene WT1 and glioblastoma.